Based on the Alnylam Pharmaceuticals Inc stock forecast from 23 analysts, the average analyst target price for Alnylam Pharmaceuticals Inc is USD 286.80 over the next 12 months. Alnylam Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alnylam Pharmaceuticals Inc is Bullish , which is based on 8 positive signals and 3 negative signals. At the last closing, Alnylam Pharmaceuticals Inc’s stock price was USD 245.44. Alnylam Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, -0.55% over the past month and +35.50% over the last year.
No recent analyst target price found for Alnylam Pharmaceuticals Inc
No recent average analyst rating found for Alnylam Pharmaceuticals Inc
Company Overview Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Read Less
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary ...Read More
Frequently Asked Questions About Alnylam Pharmaceuticals Inc (ALNY) Stock
Based on ratings from 23 analysts Alnylam Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 39 buy, 1 sell and 12 hold ratings.
Unfortunately we do not have enough data on ALNY's stock to indicate if its a good dividend stock.
Based on targets from 23 analysts, the average taret price for ALNY is USD 286.80 over the next 12 months. The maximum analyst target price is USD 400 while the minimum anlayst target price is USD 125.
Unfortunately we do not have enough data on ALNY's stock to indicate if its overvalued.
The last closing price of ALNY's stock was USD 245.44.
The most recent market capitalization for ALNY is USD 31.66B.
Based on targets from 23 analysts, the average taret price for ALNY is projected at USD 286.80 over the next 12 months.
This means that ALNY's stock price may go up by +16.85% over the next 12 months.
We can't find any ETFs which contains Alnylam Pharmaceuticals Inc's stock.
As per our most recent records Alnylam Pharmaceuticals Inc has 2,100 Employees.
Alnylam Pharmaceuticals Inc's registered address is 675 West Kendall Street, Cambridge, MA, United States, 02142.
You can get more information about it from Alnylam Pharmaceuticals Inc's website at https://www.alnylam.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Alnylam Pharmaceuticals Inc (ALNY) Stock
Based on ratings from 23 analysts Alnylam Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 39 buy, 1 sell and 12 hold ratings.
Unfortunately we do not have enough data on ALNY's stock to indicate if its a good dividend stock.
Based on targets from 23 analysts, the average taret price for ALNY is USD 286.80 over the next 12 months. The maximum analyst target price is USD 400 while the minimum anlayst target price is USD 125.
Unfortunately we do not have enough data on ALNY's stock to indicate if its overvalued.
The last closing price of ALNY's stock was USD 245.44.
The most recent market capitalization for ALNY is USD 31.66B.
Based on targets from 23 analysts, the average taret price for ALNY is projected at USD 286.80 over the next 12 months.
This means that ALNY's stock price may go up by +16.85% over the next 12 months.
We can't find any ETFs which contains Alnylam Pharmaceuticals Inc's stock.
As per our most recent records Alnylam Pharmaceuticals Inc has 2,100 Employees.
Alnylam Pharmaceuticals Inc's registered address is 675 West Kendall Street, Cambridge, MA, United States, 02142.
You can get more information about it from Alnylam Pharmaceuticals Inc's website at https://www.alnylam.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ALNY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
